Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
This article was originally published in The Pink Sheet
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
You may also be interested in...
German Merck is seeking a buyer or partner for its consumer health unit, which brought in sales of €860m last year and includes big vitamin brands Seven Seas and Neurobion.
FDA could soon receive an NDA from non-profit research group Ibis Reproductive Health and HRA Pharma, for an oral contraceptive switch in the US.
BC, Goody's, Monistat marketer boosts domestic and international OTC revenues immediately with C.B. Fleet acquisition, looks ahead to manufacturing expansion.